Accessibility Menu
AbCellera Biologics logo

AbCellera Biologics

(NASDAQ) ABCL

Current Price$3.64
Market Cap$1.09B
Since IPO (2020)-94%
5 Year-90%
1 Year+24%
1 Month-7%

AbCellera Biologics Financials at a Glance

Market Cap

$1.09B

Revenue (TTM)

$75.13M

Net Income (TTM)

$-146.41M

EPS (TTM)

$-0.49

P/E Ratio

-7.36

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$3.64

Volume

104,205

Open

$3.47

Previous Close

$3.61

Daily Range

$3.42 - $3.67

52-Week Range

$1.89 - $6.51

Estimated Earnings Date

N/A

ABCL: Motley Fool Moneyball Superscore

48

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AbCellera Biologics

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Industry

Life Sciences Tools and Services

Employees

562

CEO

Carl Lars G. Hansen, PhD

ABCL Financials

Key Financial Metrics (TTM)

Gross Margin

TBD

Operating Margin

TBD

Net Income Margin

TBD

Return on Equity

-14%

Return on Capital

TBD

Return on Assets

TBD

Earnings Yield

-13.59%

Dividend Yield

0.00%

Payout Ratio

TBD

Stock Overview

Market Cap

$1.09B

Enterprise Value

TBD

Shares Outstanding

303.16M

Float %

TBD

Volume

104.20K

Short Interest

0.00%

Avg. Volume

4.17M

FCF Yield

TBD

Financials (TTM)

Gross Profit

$75.13M

Operating Income

$217.10M

EBITDA

$155.42M

Operating Cash Flow

$131.29M

Capital Expenditure

$42.77M

Free Cash Flow

$174.07M

Cash & ST Invst.

$560.33M

Total Debt

$143.22M

AbCellera Biologics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$44.85

+8.9%

Gross Profit

$36.93

-4.2%

Gross Margin

82.34%

-0.5%

Market Cap

$1.09B

N/A

Market Cap/Employee

$1.82

N/A

Employees

562

N/A

Net Income

$8.95

+0.3%

EBITDA

$20.66

+0.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$155.01

+0.8%

Accounts Receivable

$58.29

+1.7%

Inventory

$6.34

N/A

Long Term Debt

$137.40

+2.3%

Short Term Debt

$5.82

+1.3%

Return on Assets

-10.78%

+0.9%

Return on Invested Capital

2.84%

+1.1%

Free Cash Flow

$42.96

+2.1%

Operating Cash Flow

$33.54

+5.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XERSXeris Biopharma Holdings, Inc.
$6.05-1.15%
BHVNBiohaven Ltd.
$11.55+0.26%
JANXJanux Therapeutics, Inc.
$13.52-0.66%
SIONSionna Therapeutics, Inc.
$34.14-6.57%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.10-0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$49.69+0.00%
TSLSDirexion Shares ETF Trust - Direxion Daily Tsla Bear 1x Shares
$5.64+0.00%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$70.60-0.00%

Questions About ABCL

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.